Autopsy report · NCT01015300

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

“Study terminated due to low accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Dartmouth-Hitchcock Medical Center

Sponsor type

University, hospital or other

Conditions

Hemangioblastomas; Von Hippel Lindau Disease

Interventions

Avastin

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
  “The study was terminated due to low accrual.” (95% match in meaning)
• Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
  “Study has been terminated due to poor accrual.” (95% match in meaning)
• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
  “Study was terminated due to poor accrual” (95% match in meaning)
• Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
  “Study was terminated due to lack of accrual” (94% match in meaning)
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
  “Study terminated due to slow/insufficient accrual.” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.